1 , investigators, research staff, and the sponsor study team
were masked to a patient's treatment allocation until the bli
2 anging study, 3 independent nuclear medicine physicians who
were masked to all clinical information read PET/CT scans fro
3 cting data, and the participants, caregivers, and assessors
were masked to allocation.
4 Assessors
were masked to allocation.
5 Neither participants nor investigators
were masked to dose allocation.
6 Participants and study personnel
were masked to group allocation.
7 Guardians
were masked to group assignment.
8 study drugs, assessed the outcomes, and collected the data
were masked to group assignment.
9 ent was ensured and patients, field team, and investigators
were masked to group assignment.
10 Participants, investigators, and trial sponsor
were masked to group assignment.
11 Research staff, clinicians, patients, and caregivers
were masked to group assignment.
12 ators and individuals involved in the analysis of the trial
were masked to group assignment.
13 Patients, investigators, and clinical staff
were masked to patient allocation until after statistical ana
14 or, the investigators, other study site staff, and patients
were masked to patient-level tumour PD-L1 biomarker results.
15 te staff (except for the unmasked pharmacist), and patients
were masked to pembrolizumab versus saline placebo administra
16 All trial personnel and patients
were masked to sequence and treatment allocation.
17 assessments (except independent study drug administrators)
were masked to study assignment.
18 ipants, clinicians, pharmacists, trial nurses, and midwives
were masked to study group assignment throughout the trial.
19 Patients, investigators, and the funder of the study
were masked to study treatment.
20 Postoperative assessments
were masked to the allocated intervention.
21 Participants
were masked to the existence of two incentive sizes.
22 Participants and relevant study personnel
were masked to the random assignment until completion of the
23 The TECS readers
were masked to the results of the FTF examination.
24 The investigators who performed the index test
were masked to the results of the reference test and all othe
25 Sponsors, investigators, study site personnel, and patients
were masked to the treatment allocation throughout the study.
26 ors, pharmacists, and members of the trial management group
were masked to the treatment allocation.
27 mittee, EDSS raters, laboratory personnel, and radiologists
were masked to the treatment assignment, but investigators an
28 Patients, investigators, and site staff
were masked to the treatment assignment.
29 the 3-month blinded period, both patients and the assessors
were masked to the treatment group while the unmasked program
30 Investigators
were masked to the type of medication.
31 Study staff and patients
were masked to training type.
32 Participants and all study personnel
were masked to treatment allocation until the database was lo
33 Participants and investigators
were masked to treatment allocation until the end of the foll
34 Patients, investigators, and study team members
were masked to treatment allocation.
35 Investigators, clinicians, and patients
were masked to treatment allocation.
36 Core laboratories and clinical event assessors
were masked to treatment allocation.
37 tients, physicians, and the investigators who analysed data
were masked to treatment allocation.
38 Participants, study investigators, and field workers
were masked to treatment allocation.
39 Neither participants nor investigators
were masked to treatment allocation.
40 Participants, study investigators, and all study staff
were masked to treatment allocation.
41 All patients, investigators, study staff, and pharmacists
were masked to treatment allocation.
42 Participants and investigators
were masked to treatment assignment until week 96.
43 took measurements of the lesions nor the attending doctors
were masked to treatment assignment.
44 Investigators, patients, and the funder
were masked to treatment assignment.
45 Patients, investigators, and study personnel
were masked to treatment assignment.
46 Participants and clinicians
were masked to treatment assignment.
47 Participants, investigators, and assessors
were masked to treatment assignment.
48 All patients and study personnel
were masked to treatment assignments.
49 ians, and sponsor representatives advising on trial conduct
were masked to trial group assignments.
50 and investigators, but not staff administering the vaccine,
were masked to vaccine allocation.